Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 15 of the 23 sources its claims cite were checked for support.
Abstract
Mitochondrial dysfunction is one of the possible mechanisms by which azole resistance can occur in Candida glabrata. Cells with mitochondrial DNA deficiency (so-called "petite mutants") upregulate ATP binding cassette (ABC) transporter genes and thus display increased resistance to azoles. Isolation of such C. glabrata mutants from patients receiving antifungal therapy or prophylaxis has been rarely reported. In this study, we characterized two sequential and related C. glabrata isolates recovered from the same patient undergoing azole therapy. The first isolate (BPY40) was azole susceptible (fluconazole MIC, 4 μg/ml), and the second (BPY41) was azole resistant (fluconazole MIC, >256 μg/ml). BPY41 exhibited mitochondrial dysfunction and upregulation of the ABC transporter genes C. glabrata CDR1 (CgCDR1), CgCDR2, and CgSNQ2. We next assessed whether mitochondrial dysfunction conferred a selective advantage during host infection by testing the virulence of BPY40 and BPY41 in mice. Surprisingly, even with in vitro growth deficiency compared to BPY40, BPY41 was more virulent (as judged by mortality and fungal tissue burden) than BPY40 in both systemic and vaginal murine infection models. The increased virulence of the petite mutant correlated with a drastic gain of fitness in mice compared to that of its parental isolate. To understand this unexpected feature, genome-wide changes in gene expression driven by the petite mutation were analyzed by use of microarrays during in vitro growth. Enrichment of specific biological processes (oxido-reductive metabolism and the stress response) was observed in BPY41, all of which was consistent with mitochondrial dysfunction. Finally, some genes involved in cell wall remodelling were upregulated in BPY41 compared to BPY40, which may partially explain the enhanced virulence of BPY41. In conclusion, this study shows for the first time that mitochondrial dysfunction selected in vivo under azole therapy, even if strongly affecting in vitro growth characteristics, can confer a selective advantage under host conditions, allowing the C. glabrata mutant to be more virulent than wild-type isolates.
Overview
CoChat Summary
TL;DR
A clinical *Candida glabrata* petite mutant (BPY41) that arose after azole therapy was azole resistant and, despite in vitro growth deficiency, was more virulent and fitter than its azole-susceptible parent (BPY40) in murine systemic and rat vaginal infection models. An in vitro-generated petite mutant (DSY4339) did not show this enhanced virulence, suggesting the origin/selection context of mitochondrial dysfunction matters.
Key findings
- BPY41 was azole resistant (fluconazole MIC >256 μg/ml) versus BPY40 (fluconazole MIC 4 μg/ml), with cross-resistance to itraconazole and voriconazole, and overexpressed *CgCDR1*, *CgCDR2*, *CgSNQ2*, and *CgPDR1* without a detected *CgPDR1* mutation.
- BPY41 showed mitochondrial dysfunction: no growth on glycerol, absent SYTO18 mitochondrial staining, no recoverable mitochondrial DNA, and strongly reduced oxygen consumption.
- BPY41 was more virulent than BPY40 in mice: lower LD50s (BPY41 3.45 × 10^7 CFU immunocompetent and 2.3 × 10^7 CFU immunosuppressed vs. BPY40 7.2 × 10^7 and 6.8 × 10^7 CFU), higher tissue burdens in kidney, spleen, and liver at day 7, and slower vaginal clearance in rats.
- The in vitro-generated petite DSY4339 had higher LD50s (2.81 × 10^8 CFU immunocompetent and 1.65 × 10^8 CFU immunosuppressed) and lowest tissue burdens, with virulence not significantly different from BPY40.
Methods
- Two sequential related clinical *C. glabrata* isolates from the same patient were studied: BPY40 (azole-susceptible parent) and BPY41 (azole-resistant petite mutant); DSY4339 was generated in vitro from BPY40 by ethidium bromide exposure.
- Murine systemic infection models used female BALB/c mice for survival, LD50 determination, and tissue burden (liver, spleen, kidney); a rat vaginal mucosa infection model used oophorectomized female Wistar rats. In vitro and in vivo fitness competitions mixed BPY40 and BPY41 and distinguished them by growth on fluconazole.
- Genome-wide expression was analyzed by custom *C. glabrata* Agilent microarrays with three biological replicates; genes were included if expression changed at least 2-fold between BPY41 and BPY40 in at least two independent experiments with corrected *P* < 0.05. qRT-PCR measured *CgCDR1*, *CgCDR2*, *CgSNQ2*, *CgPDR1*, and *CgYPS*.
Limitations
- The paper states it cannot exclude that the in vitro- or in vivo-generated mitochondrial mutants also contain nuclear mutations that decrease or increase virulence, respectively.
- The paper notes that the exact regulatory mechanisms behind ABC transporter upregulation in petite mutants remain largely unresolved.
- The provided text is truncated in the Results, so later analyses and the full discussion are not available here; the paper’s statement beginning “Our current data cannot confirm…” is cut off.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 5 Not checked · 18 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“upregulation of the ABC transporter genes *C. glabrata CDR1* (*CgCDR1*), *CgCDR2*, and *CgSNQ2*”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Could not verifycites [14] sourceExperimental — accuracy not yet measured
The Results section on ABC-transporter expression reports that CgCDR1, CgCDR2, and CgSNQ2 are not always upregulated together. Searches for BPY41 and for BPY41 with the three gene names found no passage reporting its expression profile; the passage about BPY55 concerns a different strain. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [35] source
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“BPY41 exhibited mitochondrial dysfunction”
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
“BPY41 exhibited typical features of a petite phenotype, including the absence of growth in glycerol-containing medium and absence of mitochondrial staining with SYTO18 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > Abstract
What the sources say
- Supportedcites [14] source
The Results section, “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates,” identifies BPY41 as having altered mitochondrial respiratory capacity, based on its inability to grow on glycerol as the sole carbon source and defects in mitochondrial DNA. This supports the paraphrase that BPY41 exhibited mitochondrial dysfunction. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Characteristics of BPY41, a clinical petite mutant isolate. · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, *C. glabrata* can develop azole resistance at a relatively high frequency ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] source
The Results report that azole-susceptible C. glabrata generated fluconazole-resistant cells in vitro at frequencies of 2 × 10−4 to 4 × 10−4. The paper describes this as high-frequency azole resistance, supporting the claim that the yeast can develop azole resistance at a relatively high frequency. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Remarkably, loss of mitochondrial function in *C. glabrata* is associated with acquisition of azole resistance ([33](#B33)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > INTRODUCTION
What the sources say
- Supportedcites [33] source
The Discussion explicitly links loss of mitochondrial function in C. glabrata to acquisition of azole resistance. The Abstract likewise reports that high-frequency azole resistance acquired in vitro was linked to mitochondrial loss. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
§ Loss of Mitochondrial Functions Associated with Azole Resistance in *Candida glabrata* Results in Enhanced Virulence in Mice[▿](#FN2),[†](#FN1) > RESULTS > Characteristics of BPY41, a clinical petite mutant isolate.
What the sources say
- Supportedcites [14] source
In Results, under “Isolation and Characterization of CgPDR1 Alleles from C. glabrata Clinical Isolates” (page not provided), BPY41 is listed among the azole-resistant isolates that were exceptions to the observed occurrence of CgPDR1 mutations. (LLM, conf=0.93)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
18 more claims · 1 with their cited sources checked
Create a free account to see all 36 claims and every source verdict.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apparently, the inactivation of these metabolic signaling pathways promotes survival during resistance evolution in both species (22).”
From Divergent mitochondrial responses and metabolic signal pathways secure the azole resistance in Crabtree-positive and negative Candida species (2024) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The virulent analyses, based on mortality and fungal tissue burden in both systemic and vaginal murine infection models, suggested higher virulence of BPY41 than BPY40.”
From Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival (2021) · cites this paper as [93]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An association of decreased fluconazole susceptibility with mitochondrial dysfunction in C. glabrata has been reported by several laboratories (7–12).”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction in pathogenic fungi or model yeast causes altered susceptibilities to antifungal drugs.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Ferrari et al. (9) demonstrated that a mitochondrial deficiency in C. glabrata strain BPY41 caused resistance to azoles associated with the upregulation of ABC transporter genes CgCDR1, CgCDR2, and CgSNQ2.”
From Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants (2013) · cites this paper as [9]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Dujon, B., Sherman, D., Fischer, G., Durrens, P., Casaregola, S., Lafontaine, I., de Montigny, J., Marck, C., Neuvéglise, C., Talla, E., et al. (2004) · Nature · doi:10.1038/nature02579 · Cited by 1,623 · cited 1×
“species, to which Saccharomyces cerevisiae also belongs (13).”
BackgroundChanging epidemiology of systemic fungal infections
Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524 · cited 1×
“glabrata has increased in the last decade, and this species now ranks as the second or third most frequently isolated Candida species among all reported cases of candidiasis (30).”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 3×
“The major mechanism involved in azole resistance is based on the overexpression of ATP binding cassette (ABC) transporters (34).”
BackgroundSelf-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Self-citationFerrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 10×
“CgCDR1, CgCDR2, CgSNQ2, and CgPDR1 are overexpressed in BPY41, which is consistent with the azole resistance phenotype (14, 35).”
BackgroundMethodInfluentialSelf-citationKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284 · cited 15×
“The rat was considered colonized when at least 1 CFU was present in the vaginal lavage fluid.”
BackgroundMethodInfluentialRSAT: regulatory sequence analysis tools
Thomas-Chollier, M., Sand, O., Turatsinze, J.-V., Janky, R., Defrance, M., Vervisch, E., Brohee, S., & van Helden, J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn304 · Cited by 278
Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants
DeRisi, J., van den Hazel, B., Marc, P., Balzi, E., Brown, P., Jacq, C., & Goffeau, A. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01294-1 · Cited by 276
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Self-citation
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“This mutant phenotype has been recovered clinically (Bouchara et al., 2000; Ferrari et al., 2011), but is not common among clinical isolates.”
BackgroundInfluentialAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
“glabrata, as well as loss of mitochondrial functions, not only mediate antifungal (azole) resistance but also enhance virulence in animal models [41–43].”
BackgroundMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Self-citationCandida glabrata: A review of its features and resistance
Rodrigues, C. F., Silva, S., & Henriques, M. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2009-3 · Cited by 268
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“glabratas involve ‘petite mutants’, which are characterized by a lack of mitochondrial DNA and mitochondrial dysfunction, and which also show upregulation of ABC transporter genes, improved fitness, and increased resistance towards azoles [101].”
BackgroundShingu-Vazquez, M., & Traven, A. (2011) · Eukaryotic Cell · doi:10.1128/ec.05184-11 · Cited by 209
“mitochondrial mutants observed in animal infection models (1, 4, 10, 19, 25, 64).”
BackgroundGlobal Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Emerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival
Hassan, Y., Chew, S. Y., & Than, L. T. L. (2021) · Journal of Fungi · doi:10.3390/jof7080667 · Cited by 170
Candida albicans and Candida glabrata : global priority pathogens
Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-23 · Cited by 180
Drug-Resistant Candida glabrata Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152
Multidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Maubon, D., Garnaud, C., Calandra, T., Sanglard, D., & Cornet, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3404-7 · Cited by 162
Self-citationCandida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“Testing the virulence of the “petite mutants” in mice with systemic and vaginal murine infection models, the authors showed that, even with in vitro growth deficiency, BPY41 was more virulent than BPY40.”
BackgroundResultInfluentialContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110
“glabrata in host interactions [34].”
Self-citationThomas, E., Roman, E., Claypool, S., Manzoor, N., Pla, J., & Panwar, S. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00889-13 · Cited by 105
“That study (7) shows that defects in mitochondrial function confer selective advantage to the strain by increasing its fitness in the host.”
BackgroundMolecular Mechanisms of Action of Herbal Antifungal Alkaloid Berberine, in Candida albicans
Dhamgaye, S., Devaux, F., Vandeputte, P., Khandelwal, N. K., Sanglard, D., Mukhopadhyay, G., & Prasad, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104554 · Cited by 101
“glabrata is well documented [43].”
Self-citationResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Sun, N., Fonzi, W., Chen, H., She, X., Zhang, L., Zhang, L., & Calderone, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-12 · Cited by 94
“(9) demonstrated that a mitochondrial deficiency in C.”
BackgroundAzole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
Drug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Hosting Infection: Experimental Models to Assay Candida Virulence
MacCallum, D. M. (2012) · International Journal of Microbiology · doi:10.1155/2012/363764 · Cited by 80
“In addition, this model has identified a petite mutant, strains expressing hyperactive alleles of the transcription factor gene PDR1 and the ace2 null mutant as being more virulent than their parent strains [88, 105, 121].”
BackgroundMethodChen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Neubauer, M., Zhu, Z., Penka, M., Helmschrott, C., Wagener, N., & Wagener, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13167 · Cited by 76
“While this is the case for most important pathogenic species, e.g., the petitenegative yeast Candida albicans or Aspergillus fumigatus, at least some pathogenic yeasts like C. glabrata can survive without mtDNA (petite-positive) (Ferrari et al., 2011).”
BackgroundInfluentialAspergillus terreus: Novel lessons learned on amphotericin B resistance
Posch, W., Blatzer, M., Wilflingseder, D., & Lass‐Flörl, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx119 · Cited by 82
Singh, A., Yadav, V., & Prasad, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039812 · Cited by 72
Verma, S., Shakya, V. P. S., & Idnurm, A. (2018) · Virulence · doi:10.1080/21505594.2017.1414133 · Cited by 67
Tipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 67
“Even if their growth rate is compromised in 32 laboratory-grown conditions, these mutants can still be obtained from patient samples, thus 33 suggesting that their growth deficit can still be compensated by other yet-unknown factors in the 34 host (Ferrari et al., 2011c, Ferrari et al., 2011a).”
BackgroundSelf-citationEmergence and evolution of virulence in human pathogenic fungi
Siscar-Lewin, S., Hube, B., & Brunke, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.12.013 · Cited by 75
Orta‐Zavalza, E., Guerrero‐Serrano, G., Gutiérrez‐Escobedo, G., Cañas‐Villamar, I., Juárez‐Cepeda, J., Castaño, I., & De Las Peñas, A. (2013) · Molecular Microbiology · doi:10.1111/mmi.12247 · Cited by 61
“…transporters engage genetic modifications, such as the acquisition of gain of function mutations in Pdr1(Ferrari et al., 2009), loss of mitochondrial function (Kaur et al., 2004; Ferrari et al., 2011) and increased gene dosage of transporters by chromosomal rearrangements (Polakova et al., 2009).”
BackgroundComparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61
Self-citationCastanheira, M., Deshpande, L. M., Davis, A. P., Carvalhaes, C. G., & Pfaller, M. A. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.05.004 · Cited by 63
Vincent, B. M., Langlois, J.-B., Srinivas, R., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., Tidor, B., Buchwald, S. L., & Lindquist, S. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.016 · Cited by 58
“Another critical challenge will be to determine if mitochondrial inhibitors can be effective against Candida glabrata, in which loss of mitochondrial respiration appears to increase azole resistance through induction of drug efflux (Ferrari et al., 2011).”
Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays
Delavy, M., Santos, A. R. D., Heiman, C. M., & Coste, A. T. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00019 · Cited by 66
Delavy, M., Cerutti, L., Croxatto, A., Prod’hom, G., Sanglard, D., Greub, G., & Coste, A. T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03000 · Cited by 62
“…in fluconazole resistance are well-known, the extensive diversity of the mutations that can occur makes difficult or even impossible to elaborate polymerase chain reaction (PCR)-based methods assessing C. albicans azole resistance (Morio et al., 2010; Ferrari et al., 2011; Vandeputte et al., 2012).”
BackgroundSelf-citationThe effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 78
“This data points out, that these mutations can positively and negatively affect virulence as well, depending on the fungal strains and experimental setup (Ferrari et al. 2011a).”
BackgroundDiagnosis and Treatment of Candidemia in the Intensive Care Unit
Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693704 · Cited by 72
Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
“glabrata clinical isolate not only exhibited mitochondrial dysfunction and upregulation of CDR1 and CDR2, but also was more virulent than its susceptible counterpart in both systemic and vaginal murine infection models [52].”
BackgroundVandeputte, P., Pradervand, S., Ischer, F., Coste, A. T., Ferrari, S., Harshman, K., & Sanglard, D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00134-12 · Cited by 51
Self-citationMilbemycins: More than Efflux Inhibitors for Fungal Pathogens
Silva, L. V., Sanguinetti, M., Vandeputte, P., Torelli, R., Rochat, B., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02040-12 · Cited by 49
“Agilent’s OneColor Quick Amp labeling kit (Agilent Technologies) was used to generate fluorescent cRNA as previously described (32).”
MethodSelf-citationBadrane, H., Cheng, S., Dupont, C., Hao, B., Driscoll, E., Morder, K., Liu, G., Newbrough, A., Fleres, G., Kaul, D., et al. (2023) · doi:10.21203/rs.3.rs-2706400/v1 · Cited by 48
Deletion of ADA2 Increases Antifungal Drug Susceptibility and Virulence in Candida glabrata
Yu, S.-J., Chang, Y.-L., & Chen, Y.-L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01924-17 · Cited by 43
The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida
Lewis, R. E., Viale, P., & Kontoyiannis, D. P. (2012) · Virulence · doi:10.4161/viru.20746 · Cited by 46
“glabrata isolates selected in vivo where triazole resistance developed from mitochondrial DNA deficiency independent of gain-of-function mutations in drug efflux pumps.(49) Interestingly, these petite mutants displayed enhanced expression of stress response pathways and cell wall remodeling, similar to that reported a…”
BackgroundResultPaul, S., Bair, T. B., & Moye-Rowley, W. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03921-14 · Cited by 45
“glabrata strains containing activated Pdr1 also exhibit increased virulence in murine models of infection have been obtained (13, 14).”
BackgroundInfluentialA novel hybrid iron regulation network combines features from pathogenic and nonpathogenic yeasts
Gerwien, F., Safyan, A., Wisgott, S., Hille, F., Kaemmer, P., Linde, J., Brunke, S., Kasper, L., & Hube, B. (2016) · mBio · doi:10.1128/mbio.01782-16 · Cited by 47
“glabrata Agilent Array, GPL10713 [73]), hybridized using a Gene Expression Hybridization kit (Agilent) as described previously (73), and scanned using a GenePix 4200AL scanner (software, GenePix Pro 6.”
MethodRodrigues, C. F., & Henriques, M. (2017) · Pathogens · doi:10.3390/pathogens6040062 · Cited by 49
Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 45
“posed as another mechanism involved in azole resistance [9].”
BackgroundMechanisms of azole resistance among clinical isolates of Candida glabrata in Poland
Szweda, P., Gucwa, K., Romanowska, E., Dzierz˙anowska-Fangrat, K., Naumiuk, Ł., Brillowska-Da˛browska, A., Wojciechowska-Koszko, I., & Milewski, S. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000062 · Cited by 43
“glabrata resistance to azoles, such as mitochondrial dysfunction (Ferrari et al., 2011) and calcium signalling (Kaur et al.”
BackgroundCan Saccharomyces cerevisiae keep up as a model system in fungal azole susceptibility research?
Demuyser, L., & Dijck, P. V. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.02.002 · Cited by 46
Candida glabrata: a deadly companion?
Bolotin‐Fukuhara, M., & Fairhead, C. (2014) · Yeast · doi:10.1002/yea.3019 · Cited by 41
“These facts, in turn, may explain the clinical failure of antifungal therapy in this species (Bouchara et al., 2000; Ferrari et al., 2011).”
BackgroundSnell, S. B., Foster, T. H., & Haidaris, C. G. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2011.01039.x · Cited by 48
“treatment, as well as to enhance its virulence in vivo (10).”
BackgroundFang, Y., Hu, L., Zhou, X., Jaiseng, W., Zhang, B., Takami, T., & Kuno, T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05126-11 · Cited by 43
“reported that the loss of mitochondrial functions associated with azole resistance in Candida glabrata also resulted in enhanced virulence in mice (18).”
BackgroundMechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China
Yao, D., Chen, J., Chen, W., Li, Z., & Hu, X. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s202058 · Cited by 42
“CgCDR1, CgCDR2, and CgSNQ2 have been examined previously.(34,35) Shin et al(36) discovered 2 strains of C.”
BackgroundSiscar-Lewin, S., Gabaldón, T., Aldejohann, A. M., Kurzai, O., Hube, B., & Brunke, S. (2021) · mBio · doi:10.1128/mbio.01128-21 · Cited by 36
“ating) genes PDR1 and CDR1, and some transcription of heat shock protein-encoding genes such as HSP12 and HS42 and SGA1 (23, 58).”
BackgroundResultInfluentialSusceptibility of Candida glabrata biofilms to echinocandins: alterations in the matrix composition
Rodrigues, C. F., Rodrigues, M. E., & Henriques, M. (2018) · Biofouling · doi:10.1080/08927014.2018.1472244 · Cited by 35
“Not surprisingly, the MBEC results evidenced the higher resistant profile of biofilm cells to antifungal agents than planktonic cells (Lewis et al. 2002; Al-Fattani and Douglas 2004; Ferrari et al. 2011; Grandesso et al. 2012; De Luca et al. 2012).”
ResultRodrigues, C. F., Gonçalves, B., Rodrigues, M. E., Silva, S. M., Azeredo, J., & Henriques, M. (2017) · Mycopathologia · doi:10.1007/s11046-017-0135-7 · Cited by 36
Nagi, M., Tanabe, K., Ueno, K., Nakayama, H., Aoyama, T., Chibana, H., Yamagoe, S., Umeyama, T., Oura, T., Ohno, H., et al. (2013) · Molecular Microbiology · doi:10.1111/mmi.12189 · Cited by 34
“Another study (Ferrari et al., 2011) reported that the cfu recovered from kidneys was about 10 times larger than that from either the spleens or the livers of BALB/c mice infected with C. glabrata, suggesting that growth of C. glabrata after dissemination was targeted more to the kidneys than to…”
BackgroundMethodResultInfluentialDhar, R., Missarova, A., Lehner, B., & Carey, L. B. (2019) · eLife · doi:10.7554/elife.38904 · Cited by 36
“…is associated with elevated tolerance to some antifungal drugs (Hallstrom and Moye-Rowley, 2000; Brun et al., 2004; Zhang and Moye-Rowley, 2001) and respiration deficient strains are often iso- lated from drug-treated patients (Bouchara et al., 2000; Ferrari et al., 2011; Peng et al., 2012).”
BackgroundKumari, S., Kumar, M., Khandelwal, N., Kumari, P., Varma, M., Vishwakarma, P., Shahi, G., Sharma, S., Lynn, A. M., Prasad, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202993 · Cited by 32
Rodrigues, C. F., & Henriques, M. (2018) · Genes · doi:10.3390/genes9040205 · Cited by 32
Sorbic acid stress activates the Candida glabrata high osmolarity glycerol MAP kinase pathway
Jandric, Z., Gregori, C., Klopf, E., Radolf, M., & Schüller, C. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00350 · Cited by 28
“325 ng of Cy3 labeled cRNA were hybridized to the custom C. glabrata GE 8 × 15 K arrays [Agilent eArray Design 017617; GPL10713 (Ferrari et al., 2011b)].”
Gale, A. N., Pavesic, M. W., Nickels, T. J., Xu, Z., Cormack, B. P., & Cunningham, K. W. (2023) · mSphere · doi:10.1128/msphere.00254-23 · Cited by 27
Arastehfar, A., Daneshnia, F., Hovhannisyan, H., Fuentes, D., Cabrera, N., Quinteros, C., Ilkit, M., Ünal, N., Hilmioğlu-Polat, S., Jabeen, K., et al. (2023) · mBio · doi:10.1128/mbio.01180-23 · Cited by 27
“Furthermore, their effect in the host has remained controversial, with some studies reporting substantially higher mortality and fungal burdens in petite strain-infected mice (14), whereas other studies have found otherwise (15, 17).”
BackgroundInfluentialTati, S., Jang, W. S., Li, R. Q., Kumar, R., Puri, S., & Edgerton, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061480 · Cited by 28
Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms
Rodrigues, C. F., Alves, D. F., & Henriques, M. (2018) · Microorganisms · doi:10.3390/microorganisms6040123 · Cited by 27
Antivirulence and avirulence genes in human pathogenic fungi
Siscar-Lewin, S., Hube, B., & Brunke, S. (2019) · Virulence · doi:10.1080/21505594.2019.1688753 · Cited by 28
Sturm, L., Geißel, B., Martin, R., & Wagener, J. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01017 · Cited by 26
Rodrigues, C. F., & Henriques, M. (2017) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936116684477 · Cited by 36
Insights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex
Silva, L. N., Ramos, L. S., de Oliveira, S. S. C., Magalhães, L. B., Squizani, E. D., Kmetzsch, L., Vainstein, M. H., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Journal of Fungi · doi:10.3390/jof6040215 · Cited by 27
“fumigatus, mitochondrial dysfunction has displayed multiple effects in fungal cells, and this can enlighten us on the enhanced efflux pumps’ activities [53,56,57].”
BackgroundWeerasinghe, H., Stölting, H., Rose, A. J., & Traven, A. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00171-22 · Cited by 31
“Petites are found in clinical isolates of C. glabrata (84, 92, 101) showing that mitochondrial dysfunction might be selected for in some cases during infection, possibly because of drug and immune resistance that result from it.”
Antifungal resistance, combinations and pipeline: oh my!
Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 22
“53 55 Modifications in mRNA stability have also been implicated in azole resistance.”
BackgroundStress Response in Candida Glabrata : Pieces of a Fragmented Picture
Jandric, Z., & Schüller, C. (2011) · Future Microbiology · doi:10.2217/fmb.11.131 · Cited by 19
Atanasova, R., Angoulvant, A., Tefit, M., Gay, F., Guitard, J., Mazier, D., Fairhead, C., & Hennequin, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069664 · Cited by 22
“glabrata infection use intravenous injection of yeasts [20–22], bypassing the crucial step of gut translocation.”
BackgroundPfaller, M. A., Castanheira, M., Lockhart, S. R., & Jones, R. N. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0091-0 · Cited by 21
“In addition to GOF mutations in CgPDR1, several genes involved in stress response, resistance to DNA damage, and cell wall structure are upregulated in azole-resistant strains of C. glabrata, all of which may contribute individually or in combination to modulate the virulence of C. glabrata [77].”
InfluentialSchrevens, S., Durandau, E., Tran, V. D. T., & Sanglard, D. (2022) · Virulence · doi:10.1080/21505594.2022.2095716 · Cited by 17
Self-citationTaylor, M. B., Skophammer, R. G., Warwick, A. R., Geck, R. C., Boyer, J. M., Students, Y., Walson, M., Large, C. R. L., Hickey, A. S.-M., Rowley, P. A., et al. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac246 · Cited by 15
Antifungal Susceptibility Testing: A Primer for Clinicians
Kuper, K. M., Coyle, E. A., & Wanger, A. R. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1146 · Cited by 19
“glabrata.(6) Echinocandin resistance among Candida species is less frequent, but can occur.”
BackgroundTruong, T., Zeng, G., Lim, T. K., Cao, T., Pang, L. M., Lee, Y. M., Lin, Q., Wang, Y., & Seneviratne, C. J. (2019) · PROTEOMICS · doi:10.1002/pmic.201900240 · Cited by 14
Cross-feeding affects the target of resistance evolution to an antifungal drug
Durand, R., Jalbert-Ross, J., Fijarczyk, A., Dubé, A. K., & Landry, C. R. (2023) · PLOS Genetics · doi:10.1371/journal.pgen.1011002 · Cited by 14
Zhou, M., Peng, J., Ren, K., Yu, Y., Li, D., She, X., & Liu, W. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04042-23 · Cited by 13
“Apparently, the inactivation of these metabolic signaling pathways promotes survival during resistance evolution in both species (22).”
BackgroundLow Glucose Mediated Fluconazole Tolerance in Cryptococcus neoformans
Bhattacharya, S., Oliveira, N. K., Savitt, A. G., Silva, V. K. A., Krausert, R. B., Ghebrehiwet, B., & Fries, B. C. (2021) · Journal of Fungi · doi:10.3390/jof7060489 · Cited by 14
“had shown the link between mitochondrial dysfunction and enhanced FLC resistance [17,18,70].”
BackgroundRodrigues, C. F., Correia, A., Vilanova, M., & Henriques, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020142 · Cited by 16
Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida
Banda-Flores, I. A., Torres‐Tirado, D., Mora-Montes, H. M., Pérez‐Flores, G., & Pérez-García, L. A. (2025) · Journal of Fungi · doi:10.3390/jof11040271 · Cited by 17
“Impor-tantly, the loss of mitochondrial function in N. glabratus has been associated with increased azole resistance and enhanced virulence in a murine infection model [94].”
Mutlu, N., Garipler, G., Akdoğan, E., & Dunn, C. D. (2014) · G3 Genes Genomes Genetics · doi:10.1534/g3.114.010330 · Cited by 11
“…segregant pools greatly facilitated the rapid identi fi cation of the dominant alleles described here, because identi fi - cation of dominant mutations typically requires either arduous construction of a genomic library or, alternatively, painstaking work to map the relevant variant (Forsburg 2001).”
BackgroundJha, A., & Kumar, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0479 · Cited by 12
Duxbury, S. J. N., Bates, S., Beardmore, R., & Gudelj, I. (2020) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2020.0761 · Cited by 16
“glabrata azoleresistant petite mutant during clinical infection identified that it had enhanced virulence but reduced in vitro fitness in the absence of the drug, compared to the sensitive coisolated type [55].”
BackgroundMitochondrial Genome Sequences of the Emerging Fungal Pathogen Candida auris
Misas, E., Chow, N. A., Gómez, O. M., Muñoz, J. F., McEwen, J. G., Litvintseva, A. P., & Clay, O. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.560332 · Cited by 14
At What Cost Echinocandin Resistance?
Clancy, C. J., & Nguyen, M. H. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir355 · Cited by 13
Asadzadeh, M., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175269 · Cited by 14
Nie, H., Liu, X., Pan, J., Li, W., Li, Z., Zhang, S., Chen, S., Miao, X., Zheng, N., & Su, S. (2017) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2017-0013 · Cited by 15
“Aliquots of 200 ng of total RNA from each sample were used in a protocol described by Ferrari et al. (2011), and 1.5 g of Cy3-labelled cRNAs were obtained from each sample.”
MethodInfluentialOkamoto, M., Nakano, K., Takahashi-Nakaguchi, A., Sasamoto, K., Yamaguchi, M., Teixeira, M. C., & Chibana, H. (2023) · Journal of Fungi · doi:10.3390/jof9020240 · Cited by 11
“Upregulation of ABC transporters by Pdr1 has also been reported in mitochondrial dysfunction, leading to azole resistance [11,14].”
BackgroundZambuzzi-Carvalho, P. F., Fernandes, A. G., Valadares, M. C., Tavares, P. D. M., Nosanchuk, J. D., Soares, C. M. D. A., & Pereira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv011 · Cited by 12
“Cells with mitochondrial DNA deficiency and upregulated ABC transporter genes display increased resistance to azoles [87,88].”
BackgroundA homologous overexpression system to study roles of drug transporters in Candida glabrata
Kumari, S., Kumar, M., Khandelwal, N., Pandey, A. K., Bhakt, P., Kaur, R., Prasad, R., & Gaur, N. A. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa032 · Cited by 9
Raman, S. B., Nguyen, M. H., Cheng, S., Badrane, H., Iczkowski, K. A., Wegener, M., Gaffen, S. L., Mitchell, A. P., & Clancy, C. J. (2013) · Infection and Immunity · doi:10.1128/iai.00743-12 · Cited by 12
Jaiswal, N., & Kumar, A. (2024) · Molecular Biotechnology · doi:10.1007/s12033-023-01017-1 · Cited by 9
“It can also promote sterol uptake [8, 9].”
Huang, S., Song, Y., Lv, G., Liu, J., Zhao, J., Wang, L.-L., & Xiang, M.-J. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1550894 · Cited by 13
Navarro-Rodríguez, P., Martín‐Vicente, A., López‐Fernández, L., Guarro, J., & Capilla, J. (2019) · Medical Mycology · doi:10.1093/mmy/myz014 · Cited by 12
Chow, E. W. L., Song, Y., Wang, H., Xu, X., Gao, J., & Wang, J. (2024) · Molecular Microbiology · doi:10.1111/mmi.15229 · Cited by 8
“Mitochondrial deficiency and azole resistance have been associated with the overexpression of Pdr1-regulated ef - flux pumps, independent of gain- of-function mutations in PDR1 (Brun et al., 2004; Ferrari et al., 2011 ; Peng et al., 2012 ).”
BackgroundMethodResultInfluentialYoo, K., Bhattacharya, S., Oliveira, N. K., Pereira de Sa, N., Matos, G. S., Del Poeta, M., & Fries, B. C. (2024) · mBio · doi:10.1128/mbio.01847-24 · Cited by 8
“In Candida glabrata , the loss of mito chondrial function is associated with the acquisition of azole resistance through the upregulation of genes encoding ABC transporters (17, 67).”
Background
Metadata
- Authors
- Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- Department of Infectious, Parasitic, and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-05
- Volume
- 55
- Issue
- 5
- Pages
- 1852-1860
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3088236
- OpenAlex
- W2098964280
- Semantic Scholar
- 8b330e8c08f4c329027f81adbc47ae8af0f15169
- Cited by
- 144
- References
- 44
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 12 · 2023: 10 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 12 · 2012: 12
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- Candida glabrata, azole resistance, mitochondrial dysfunction, petite mutants, ABC transporters, CDR1, CDR2, fluconazole, fungal virulence, antifungal therapy, cell wall remodeling, oxidative stress response, gene expression profiling, fitness cost
- MeSH terms
- Animals, Azoles, Female, Mice, Inbred BALB C, Microbial Sensitivity Tests, Molecular Sequence Data, Virulence, Gene Expression Regulation, Fungal, Computational Biology, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Microarray Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.